According to a Reuters story, the European Medicines Agency (EMA), which is the European agency for drug review similar to the Food and Drug Administration in the U.S., approved a second biosimilar drug copy of the biologic Enbrel for the treatment of rheumatoid arthritis (RA).

Click here for more